Failed trial knocks back wider use of BMS' Camzyos

Failed trial knocks back wider use of BMS' Camzyos

Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.

Bristol Myers stumbles in bid to widen heart drug’s use

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether other drugs like it would similarly struggle in testing.

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study. The post Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It appeared first on Investor's Business Daily.

BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the product's usage, BMS said Monday post-market, a development that could considerably cap its sales ceiling. ...

Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.